Mar 17, 2023 FDA calls for comments on artificial intelligence in drug manufacturing By Keo Shaw Bethany Hills Daniel Tobey Geoffrey Levitt +1 more... Show less On March 1, 2023, FDA’s Center for Drug Evaluation and Research (CDER) published a discussion paper on artificial intelligence (AI) in...
Mar 30, 2022 The moral imperative: Balancing innovation, regulation and prescription drug availability By Jim Greenwood Geoffrey Levitt We stand today on the threshold of almost unimaginable progress in defeating diseases that have ravaged humans for millennia. New...